irritable bowel syndrome

Qualified patients will have immediate access to IQuity's MS test, with expected access later to an IBD-IBS test, and a fibromyalgia test.

The agreement, with Genetic Analysis of Oslo, involves technology to detect gut dysbiosis and investment for additional tests.

The researchers used this approach to show how non-coding variation associated with human immune dysfunction alters context-specific gene programs. 

IQuity's current tests analyze gene expression patterns detected in mRNA, but the firm is also exploring the diagnostic potential of long non-coding RNAs.

The test, which detects various bacterial species in fecal samples, is expected to be submitted to US regulators before the end of this year.

Genetic Analysis CEO Kari Stenersen said the deal is a "commercial breakthrough" for the Oslo-based company.

NEW YORK (GenomeWeb News) – The nonprofit Crohn's and Colitis Canada has awarded nearly C$800,000 (US$740,000) to fund three omics research projects that will investigate genes involved in inflammatory bowel diseases (IBD) and a possible method for treating such diseases.

NEW YORK (GenomeWeb) – An international team that includes members of the "Metagenomics of the Human Intestinal Tract," or MetaHIT, consortium has come up with a new method for putting together microbial genomes and identifying species from metagenomic sequence data.

Genetic Analysis said this week that its GA-map IBS Dysbiosis test is now CE marked and available for use on clinical samples in European labs.

Pages

Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.

US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.

The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.

In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.